Gibney, G. T., Lee, S. J., Atkins, M. B., Wong, T. Z., Guerriero, J., Marron, T. U., … Wolchok, J. D. (2022). A phase II study of biomarker-driven early discontinuation of anti-PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Gibney, Geoffrey Thomas, Sandra J. Lee, Michael B. Atkins, Terence Z. Wong, Jennifer Guerriero, Thomas Urban Marron, Gary Irvin Cohen, et al. “A phase II study of biomarker-driven early discontinuation of anti-PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Gibney GT, Lee SJ, Atkins MB, Wong TZ, Guerriero J, Marron TU, et al. A phase II study of biomarker-driven early discontinuation of anti-PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Gibney, Geoffrey Thomas, et al. “A phase II study of biomarker-driven early discontinuation of anti-PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Gibney GT, Lee SJ, Atkins MB, Wong TZ, Guerriero J, Marron TU, Cohen GI, Truong T-G, Carvajal RD, Snyder B, Farwell M, Kirkwood JM, Wolchok JD. A phase II study of biomarker-driven early discontinuation of anti-PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192. JOURNAL OF CLINICAL ONCOLOGY. 2022.